1izh: Difference between revisions
New page: left|200px<br /> <applet load="1izh" size="450" color="white" frame="true" align="right" spinBox="true" caption="1izh, resolution 1.90Å" /> '''Inhibitor of HIV pr... |
No edit summary |
||
Line 1: | Line 1: | ||
[[Image:1izh.gif|left|200px]]<br /> | [[Image:1izh.gif|left|200px]]<br /><applet load="1izh" size="350" color="white" frame="true" align="right" spinBox="true" | ||
<applet load="1izh" size=" | |||
caption="1izh, resolution 1.90Å" /> | caption="1izh, resolution 1.90Å" /> | ||
'''Inhibitor of HIV protease with unusual binding mode potently inhibiting multi-resistant protease mutants'''<br /> | '''Inhibitor of HIV protease with unusual binding mode potently inhibiting multi-resistant protease mutants'''<br /> | ||
==Overview== | ==Overview== | ||
Protease inhibitors (PIs) are an important class of drugs for the | Protease inhibitors (PIs) are an important class of drugs for the treatment of HIV infection. However, in the course of treatment, resistant viral variants with reduced sensitivity to PIs often emerge and become a major obstacle to successful control of viral load. On the basis of a compound equipotently inhibiting HIV-1 and 2 proteases (PR), we have designed a pseudopeptide inhibitor, QF34, that efficiently inhibits a wide variety of PR variants. In order to analyze the potency of the inhibitor, we constructed PR species harboring the typical (signature) mutations that confer resistance to commercially available PIs. Kinetic analyses showed that these mutated PRs were inhibited up to 1,000-fold less efficiently by the clinically approved PIs. In contrast, all PR species were effectively inhibited by QF34. In a clinical study, we have monitored 30 HIV-positive patients in the Czech Republic undergoing highly active antiretroviral therapy, and have identified highly PI resistant variants. Kinetic analyses revealed that QF34 retained its subnanomolar potency against multi-drug resistant PR variants. X-ray crystallographic analysis and molecular modeling experiments explained the wide specificity of QF34: this inhibitor binds to the PR in an unusual manner, thus avoiding contact sites that are mutated upon resistance development, and the unusual binding mode and consequently the binding energy is therefore preserved in the complex with a resistant variant. These results suggest a promising route for the design of second-generation PIs that are active against a variety of resistant PR variants. | ||
==About this Structure== | ==About this Structure== | ||
1IZH is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Human_immunodeficiency_virus_1 Human immunodeficiency virus 1] with Q50 as [http://en.wikipedia.org/wiki/ligand ligand]. Active as [http://en.wikipedia.org/wiki/HIV-1_retropepsin HIV-1 retropepsin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.23.16 3.4.23.16] Full crystallographic information is available from [http:// | 1IZH is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Human_immunodeficiency_virus_1 Human immunodeficiency virus 1] with <scene name='pdbligand=Q50:'>Q50</scene> as [http://en.wikipedia.org/wiki/ligand ligand]. Active as [http://en.wikipedia.org/wiki/HIV-1_retropepsin HIV-1 retropepsin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.23.16 3.4.23.16] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1IZH OCA]. | ||
==Reference== | ==Reference== | ||
Line 18: | Line 17: | ||
[[Category: Klimkait, T.]] | [[Category: Klimkait, T.]] | ||
[[Category: Konvalinka, J.]] | [[Category: Konvalinka, J.]] | ||
[[Category: Kraeusslich, H | [[Category: Kraeusslich, H G.]] | ||
[[Category: Lepsik, M.]] | [[Category: Lepsik, M.]] | ||
[[Category: Machala, L.]] | [[Category: Machala, L.]] | ||
[[Category: Mesters, J | [[Category: Mesters, J R.]] | ||
[[Category: Mlcochova, P.]] | [[Category: Mlcochova, P.]] | ||
[[Category: Prejdova, J.]] | [[Category: Prejdova, J.]] | ||
Line 38: | Line 37: | ||
[[Category: subsite binding]] | [[Category: subsite binding]] | ||
''Page seeded by [http:// | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 13:17:21 2008'' |